This article talks about some people who give advice on what stocks to buy or sell. They think a company called Alphabet will do better soon, and they also like other companies like Progressive, D.R. Horton, and Pfizer. One of these companies makes medicine, and they did a study that shows their medicine works well for some sick people. Read from source...

1. The title of the article is misleading and sensationalized. It implies that Alphabet is in a decline or underperforming, and the author expects it to rebound sharply. However, the article does not provide any evidence or analysis to support this claim. Instead, it mentions some positive developments for Alphabet, such as partnerships with Verizon and Google Cloud Platform.
2. The article focuses on the opinions of a few analysts who have chosen other stocks for their final trades. However, these are not necessarily bad recommendations, nor do they reflect the overall performance or potential of Alphabet. Moreover, the author does not disclose any conflicts of interest or incentives that may influence the analysts' opinions.
3. The article fails to mention any negative news or challenges that Alphabet is facing, such as antitrust investigations, regulatory scrutiny, data privacy issues, competition from other tech giants, etc. These are relevant factors that affect Alphabet's stock price and long-term prospects, and the author should have addressed them in a balanced and objective manner.
4. The article ends with a promotion for Benzinga's services and products, which is irrelevant to the main topic and detracts from the credibility of the content. This also creates a potential conflict of interest between the author and the publisher, as they both benefit from driving traffic and engagement to their website.
5. The article lacks any original or insightful analysis that would help readers understand the dynamics of the stock market and the factors that influence Alphabet's performance. Instead, it relies on secondary sources, such as press releases, news wires, and social media feeds. This does not demonstrate any expertise or authority on the subject matter, nor does it provide any value to the readers.

DAN: Based on my analysis, I would suggest that you do not follow the advice of the author or the analysts mentioned in the article. They are either biased, uninformed, or misleading in their opinions and recommendations. Instead, you should conduct your own research and due diligence before making any investment decisions. You should also consider other factors that may affect Alphabet's stock price and long-term prospects, such as its financial performance, competitive advantage, growth potential, corporate governance, etc. Additionally, you should diversify your portfolio and balance your risk and reward expectations.